A new study on the persistence of neutralising antibodies to SARS-CoV-2 in the blood suggests that humoral immunity will drop 5 months after vaccination.
Francesco Maria Lavino has been appointed as Chief Executive Officer of F2G Ltd., a biopharmaceutical company, based in UK and Austria, and specialised in fungal infections.
Swiss BioVersys has received €20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.
COVID-19: Study finds neutralising antibodies to disappear rapidly
Latest NewsA new study on the persistence of neutralising antibodies to SARS-CoV-2 in the blood suggests that humoral immunity will drop 5 months after vaccination.
Change in Management
AppointmentsFrancesco Maria Lavino has been appointed as Chief Executive Officer of F2G Ltd., a biopharmaceutical company, based in UK and Austria, and specialised in fungal infections.
BioVersys gets €20m EIB loan to develop novel antibiotics
Latest NewsSwiss BioVersys has received €20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.